TILT Biotherapeutics €22 Million Financing

‘We’re really happy with the team at Scius and their support for both rounds of our financing announcements. Highlighting engagement from both investors as well as funding from the EIC has been incredibly valuable to underscore our position as industry leaders in oncolytic viruses. We were delighted by the coverage achieved in the major trade publications.’

Akseli Hemminki, CEO of TILT Biotherapeutics

Objectives

Promote TILT Biotherapeutics as a pioneer and global leader in oncolytic viral therapies
Raise awareness of the final close of its €22m round which followed rapidly on from the first close in June 2022
Highlight the €5.9m equity from the European Innovation Council (EIC) Fund as well as a €2.1 million grant from EIC’s Accelerator programme

Strategy

Liaising with the investors to co-ordinate timings and quotes for the announcement
Drafting announcement, key messages and media strategy
Pre-briefing target journalists under embargo and setting up one-on-one briefings, with further media follow up on day of release

Results

Extensive global trade media coverage (Merger Markets, BioWorld, and Endpoints)
Scandinavian press including Nordic Life Sciences

Objectives

Strategy

Results

Coverage

Social Media